Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is a pilot imaging study for women whose tumors express NIS [Na+I- symporter, sodium
iodide symporter]. Eligibility is limited to the presence of strong (3+) and/or plasma
membrane staining in > 20% of cells as determined by immunohistochemical methods. A total of
10 patients will be imaged with 124I PET/CT (serial scans over 24 hour period) to determine
radioiodide uptake and distribution in tumor tissue. Thyroid iodide uptake and retention will
be blocked beginning one week prior to 124I PET/CT scan with thyroid hormone (T3) and
methimazole (impedes organification). Tumor, organ and whole body dosimetry will be
calculated in each patient.